These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 27515812)
1. Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations. Kakar Q; Sheikh S; Ahmed I; Khan MA; Jamil M; ElMohammady H; Warsame M Acta Trop; 2016 Dec; 164():17-22. PubMed ID: 27515812 [TBL] [Abstract][Full Text] [Related]
2. Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles. Warsame M; Hassan AM; Barrette A; Jibril AM; Elmi HH; Arale AM; Mohammady HE; Nada RA; Amran JG; Muse A; Yusuf FE; Omar AS Trop Med Int Health; 2015 Apr; 20(4):510-7. PubMed ID: 25583123 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy. Warsame M; Hassan AH; Hassan AM; Arale AM; Jibril AM; Mohamud SA; Barrette A; Muse AY; Yusuf FE; Nada RA; Amran JG Trop Med Int Health; 2017 Apr; 22(4):415-422. PubMed ID: 28151566 [TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. Tahar R; Basco LK Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Smith SJ; Kamara ARY; Sahr F; Samai M; Swaray AS; Menard D; Warsame M Acta Trop; 2018 Sep; 185():363-370. PubMed ID: 29932931 [TBL] [Abstract][Full Text] [Related]
6. High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies. Adeel AA; Elnour FA; Elmardi KA; Abd-Elmajid MB; Elhelo MM; Ali MS; Adam MA; Atta H; Zamani G; Warsame M; Barrette A; Mohammady HE; Nada RA Malar J; 2016 May; 15(1):285. PubMed ID: 27209063 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021. Dorkenoo AM; Warsame M; Ataba E; Hemou M; Yakpa K; Sossou E; Mitigmsagou M; Teou CD; Caspar E; Ma L; Djadou KE; Atcha-Oubou T; Rasmussen C; Menard D Malar J; 2024 Apr; 23(1):92. PubMed ID: 38570791 [TBL] [Abstract][Full Text] [Related]
8. A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India. Srivastava P; Ratha J; Shah NK; Mishra N; Anvikar AR; Sharma SK; Das MK; Srivastava B; Valecha N Malar J; 2013 Jul; 12():247. PubMed ID: 23866298 [TBL] [Abstract][Full Text] [Related]
9. High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria. Quan H; Igbasi U; Oyibo W; Omilabu S; Chen SB; Shen HM; Okolie C; Chen JH; Zhou XN Infect Dis Poverty; 2020 Jul; 9(1):91. PubMed ID: 32653033 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes. Sitali L; Mwenda MC; Miller JM; Bridges DJ; Hawela MB; Hamainza B; Mudenda-Chilufya M; Chizema-Kawesha E; Daniels RF; Eisele TP; Nerland AH; Chipeta J; Lindtjorn B Acta Trop; 2020 Dec; 212():105704. PubMed ID: 33002448 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Awab GR; Imwong M; Pukrittayakamee S; Alim F; Hanpithakpong W; Tarning J; Dondorp AM; Day NP; White NJ; Woodrow CJ Malar J; 2016 Feb; 15():121. PubMed ID: 26917051 [TBL] [Abstract][Full Text] [Related]
12. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics. A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA Malar J; 2007 Aug; 6():108. PubMed ID: 17686173 [TBL] [Abstract][Full Text] [Related]
13. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238 [TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in Plasmodium falciparum and Plasmodium vivax dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Vanuatu and Solomon Islands prior to the introduction of artemisinin combination therapy. Gresty KJ; Gray KA; Bobogare A; Wini L; Taleo G; Hii J; Cheng Q; Waters NC Malar J; 2014 Oct; 13():402. PubMed ID: 25311473 [TBL] [Abstract][Full Text] [Related]
16. Polymorphism analysis of drug resistance markers in Plasmodium falciparum isolates from Benin. L'Episcopia M; Doderer-Lang C; Perrotti E; Priuli GB; Cavallari S; Guidetti C; Bernieri F; Menard D; Severini C Acta Trop; 2023 Sep; 245():106975. PubMed ID: 37348801 [TBL] [Abstract][Full Text] [Related]
17. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Iriemenam NC; Shah M; Gatei W; van Eijk AM; Ayisi J; Kariuki S; Vanden Eng J; Owino SO; Lal AA; Omosun YO; Otieno K; Desai M; ter Kuile FO; Nahlen B; Moore J; Hamel MJ; Ouma P; Slutsker L; Shi YP Malar J; 2012 Jul; 11():134. PubMed ID: 22540158 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. Tahita MC; Tinto H; Erhart A; Kazienga A; Fitzhenry R; VanOvermeir C; Rosanas-Urgell A; Ouedraogo JB; Guiguemde RT; Van Geertruyden JP; D'Alessandro U PLoS One; 2015; 10(9):e0137440. PubMed ID: 26368675 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Awab GR; Pukrittayakamee S; Jamornthanyawat N; Yamin F; Dondorp AM; Day NP; White NJ; Woodrow CJ; Imwong M Malar J; 2013 Mar; 12():96. PubMed ID: 23497229 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Biswas S; Escalante A; Chaiyaroj S; Angkasekwinai P; Lal AA Trop Med Int Health; 2000 Oct; 5(10):737-43. PubMed ID: 11044269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]